Literature DB >> 830792

Requirements for the solubilization of immune aggregates by complement: assembly of a factor B-dependent C3-convertase on the immune complexes.

M Takahashi, B F Tack, V Nussenzweig.   

Abstract

During the solubilization of immune precipitates BSA-rabbit antibodies to BSA by human complement, at least three stages can be distinguished. (A) Generation of alternative pathway C3-convertase sites associated with the immune complexes. During the first minutes of interaction between the immune aggregates and serum, before any solubilization has taken place, properdin (P), factor B, and C3 moieties are incorporated into the lattice. The washed precipitates have C3-convertase activity, which can be completely inhibited by antibodies to factor B, but not to C2. The assembly of the convertase is temperature-dependent, and does not take place in the absence of Mg++. The immune complex-associated C3-convertase activity decays rapidly at 37 degrees C, but it can be restored by addition of purified factor B and properdin. (B) Amplification. When the aggregates bearing C3-convertase are incubated with purified C3, solubilization takes place. It appears that solubilization is caused by the accumulation of a large number of C3 fragments on the Ag-Ab lattice. In solubilized complexes, the molar ratios of Ab/C3 are close to one. (C) Spontaneous release. The final step in the solubilization process is a secondary reaction, during which some rearrangement of the lattice takes place. It occurs in medium devoid of serum and does not require divalent cations.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 830792      PMCID: PMC2180585          DOI: 10.1084/jem.145.1.86

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  25 in total

Review 1.  Complement.

Authors:  H J Müller-Eberhard
Journal:  Annu Rev Biochem       Date:  1975       Impact factor: 23.643

2.  A new complement function: solubilization of antigen-antibody aggregates.

Authors:  G W Miller; V Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  1975-02       Impact factor: 11.205

3.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

4.  Properties of highly purified human properdin.

Authors:  J Ensky; C F Hinz; E W Todd; R J Wedgwood; J T Boyer; I H Lepow
Journal:  J Immunol       Date:  1968-01       Impact factor: 5.422

5.  Studies on the sub-unit structure of human properdin.

Authors:  J O Minta; I H Lepow
Journal:  Immunochemistry       Date:  1974-07

6.  Solid phase radioimmunoassay of properdin.

Authors:  J O Minta; I Goodkofsky; I H Lepow
Journal:  Immunochemistry       Date:  1973-05

7.  The reaction of zymosan with the properdin system in normal and C4-deficienct guinea pig serum. Demonstration of C3- and C5-cleaving multi-unit enzymes, both containing factor B, and acceleration of their formation by the classical complement pathway.

Authors:  V Brade; G D Lee; A Nicholson; H S Shin; M M Mayer
Journal:  J Immunol       Date:  1973-11       Impact factor: 5.422

8.  Antibody-complement complexes.

Authors:  W F Willoughby; M M Mayer
Journal:  Science       Date:  1965-11-12       Impact factor: 47.728

9.  Multiple sedimenting species of properdin in human serum and interaction of purified properdin with the third component of complement.

Authors:  J Chapitis; I H Lepow
Journal:  J Exp Med       Date:  1976-02-01       Impact factor: 14.307

10.  The role of properdin in the alternate pathway of complement activation.

Authors:  O Götze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1974-01-01       Impact factor: 14.307

View more
  28 in total

1.  Immune complex-FcgammaR interaction modulates monocyte/macrophage molecules involved in inflammation and immune response.

Authors:  P Barrionuevo; M Beigier-Bompadre; G C Fernandez; S Gomez; M F Alves-Rosa; M S Palermo; M A Isturiz
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

2.  Isolation and analysis of immune complexes from sera of patients with polymyalgia rheumatica and giant cell arteritis.

Authors:  A J Smith; V Kyle; T E Cawston; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1987-06       Impact factor: 19.103

3.  Dissociation of IgG antibody-mediated clumps of Trypanosoma brucei gambiense by complement.

Authors:  T Takayanagi; H Kawaguchi; Y Yabu; M Itoh; K Yano
Journal:  Parasitol Res       Date:  1991       Impact factor: 2.289

4.  C3 binds covalently to the C gamma 3 domain of IgG immune aggregates during complement activation by the alternative pathway.

Authors:  L C Antón; J M Alcolea; P Sánchez-Corral; G Marqués; A Sánchez; F Vivanco
Journal:  Biochem J       Date:  1989-02-01       Impact factor: 3.857

5.  Prevention of immune precipitation by purified components of the alternative pathway.

Authors:  J K Naama; E Holme; E Hamilton; K Whaley
Journal:  Clin Exp Immunol       Date:  1985-04       Impact factor: 4.330

6.  Initiation of the alternative pathway of murine complement by immune complexes is dependent on N-glycans in IgG antibodies.

Authors:  Nirmal K Banda; Allyson K Wood; Kazue Takahashi; Brandt Levitt; Pauline M Rudd; Louise Royle; Jodie L Abrahams; Gregory L Stahl; V Michael Holers; William P Arend
Journal:  Arthritis Rheum       Date:  2008-10

7.  Complement-mediated inhibition of immune precipitation. I. Role of the classical and alternative pathways.

Authors:  J A Schifferli; P Woo; D K Peters
Journal:  Clin Exp Immunol       Date:  1982-03       Impact factor: 4.330

8.  Deletion Variants of CFHR1 and CFHR3 Associate with Mesangial Immune Deposits but Not with Progression of IgA Nephropathy.

Authors:  Perrine Jullien; Blandine Laurent; Guillaume Claisse; Ingrid Masson; Miriana Dinic; Damien Thibaudin; Francois Berthoux; Eric Alamartine; Christophe Mariat; Nicolas Maillard
Journal:  J Am Soc Nephrol       Date:  2017-11-07       Impact factor: 10.121

9.  Complement-mediated solubilization of immune complexes in systemic lupus erythematosus.

Authors:  T Sakurai; T Fujita; I Kono; T Kabashima; K Yamane; N Tamura; H Kashiwagi
Journal:  Clin Exp Immunol       Date:  1982-04       Impact factor: 4.330

10.  Molecular distribution of preformed thyroglobulin immune complexes.

Authors:  S Husby; J Steensgaard; U Feldt-Rasmussen; J Date
Journal:  Immunology       Date:  1983-02       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.